Workflow
银诺医药-B通过聆讯 联席保荐人为中信证券、中金公司
Zheng Quan Shi Bao Wang·2025-08-04 00:50

Core Viewpoint - Yinno Pharmaceutical-B has passed the Hong Kong Stock Exchange hearing, focusing on the research and development of candidate drugs for diabetes and other metabolic diseases [1] Company Summary - Yinno Pharmaceutical's core product, Isupaglutide α, has been approved in China for the treatment of type 2 diabetes as of January 2025 and will begin commercialization in February 2025 [1] - Isupaglutide α is the first domestically approved human-derived long-acting GLP-1 receptor agonist in China, which can be used as a monotherapy or in combination with Metformin [1] Industry Summary - The GLP-1 therapy market has significant growth potential, with the global market size expected to increase from $14.7 billion in 2024 to $33.8 billion by 2028 [1] - The Chinese market is projected to grow even faster, with an expected increase from 400 million RMB in 2024 to 20.7 billion RMB by 2028 [1]